首页 > 市场调查报告书 > 製药

麻醉

市场调查报告书

商品编码

1899919

全身麻醉剂市场规模、份额和成长分析（按药物类型、给药途径、最终用途、应用领域和地区划分）－2026-2033年产业预测

General Anesthesia Drugs Market Size, Share, and Growth Analysis, By Drug Type (Propofol, Sevoflurane), By Route of Administration (Intravenous, Inhaled), By End-Use, By Application, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 260 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全身麻醉剂市场规模将达到 57.9 亿美元，到 2025 年将达到 59.9 亿美元，到 2033 年将达到 78.9 亿美元，预测期（2026-2033 年）的复合年增长率为 3.5%。

由于外科手术数量的增加和创新麻醉剂的问世，全身麻醉剂市场正经历显着增长。全身麻醉主要透过静脉注射给药，透过抑制自主神经系统反应来诱导意识丧失和缓解疼痛。这项技术尤其广泛应用于心血管手术和慢性肾臟病治疗。美容和重组手术的兴起进一步推动了市场需求，全球每年进行数百万例大型手术。新型局部麻醉剂和镇静剂等新产品核可，正成为该产业公司盈利的收入来源。因此，外科手术数量的增加和创新药物的研发预计将在未来几年推动市场扩张。

全身麻醉剂市场成长要素

癌症患者数量的不断增长是推动全身麻醉剂市场需求的主要因素。随着数百万癌症倖存者的出现，并且预计这一群体还将持续增长，对手术干预的需求也在增加，因为在癌症早期发现时，手术往往是最有效的治疗手段。肺癌、乳癌和大肠癌等常见癌症都需要手术治疗，而全身麻醉通常是有效控制疼痛和缓解焦虑的必要手段。随着越来越多的患者接受各种肿瘤的手术治疗，全身麻醉的依赖将进一步增强，医疗保健系统为满足这些日益增长的手术需求，也将推动市场向前发展。

全身麻醉剂市场的限制

全球全身麻醉剂市场的主要限制因素之一是麻醉剂相关副作用发生率的不断上升，这引发了医护人员和病患的安全疑虑。诸如呼吸系统併发症、过敏反应和术后认知障碍等不良反应的报告可能导致人们不愿意使用这些药物。监管机构也正在对某些麻醉剂的使用施加更严格的指导方针，这使得核准和市场准入变得更加复杂。此外，随着临床医生寻求更安全、创伤更小的麻醉方案，人们对区域麻醉和镇静等替代麻醉技术的兴趣日益浓厚，这可能会进一步限制市场的成长潜力。

全身麻醉剂市场趋势

全身麻醉剂市场正经历显着成长，这主要得益于旨在改善临床疗效和促进患者康復的强劲研发活动。评估各种麻醉剂（包括吸入和静脉注射麻醉药，例如Propofol）疗效的创新研究激增，从而改善了患者的体验。这种对优化麻醉通讯协定日益重视的趋势反映了个人化医疗的广泛发展，相关人员都渴望改进现有药物并开发新的製剂。此外，技术进步以及对患者安全和舒适度的日益重视也进一步推动了市场扩张，为麻醉剂的研发和应用创造了充满活力的环境。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2021-2023年营收年比比较

主要企业简介

AstraZeneca（UK）
Baxter International Inc.（USA）
Fresenius SE & Co. KGaA（Germany）
AbbVie Inc.（USA）
B. Braun Melsungen AG（Germany）
Hikma Pharmaceuticals PLC（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Mylan NV（USA）
Piramal Enterprises Limited（India）
Eisai Co., Ltd.（Japan）
F. Hoffmann-La Roche Ltd.（Switzerland）
GlaxoSmithKline plc（UK）
Johnson & Johnson（USA）
Merck & Co., Inc.（USA）
Sanofi SA（France）
Sun Pharmaceutical Industries Ltd.（India）
Takeda Pharmaceutical Company Limited（Japan）
Abbott Laboratories（USA）

结论与建议

简介目录

Product Code: SQSG30B2035

General Anesthesia Drugs Market size was valued at USD 5.79 Billion in 2024 and is poised to grow from USD 5.99 Billion in 2025 to USD 7.89 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The general anesthesia drugs market is experiencing significant growth due to the increasing number of surgical procedures and the introduction of innovative anesthetic medications. General anesthesia induces unconsciousness, pain relief, and suppresses autonomic nervous system responses, primarily through intravenous (IV) techniques, which are especially prevalent in cardiovascular and chronic renal procedures. The rise in cosmetic and reconstructive surgeries further amplifies demand, with millions of major surgeries conducted globally each year. New product approvals, like novel local anesthetics and procedural sedation agents, are emerging as lucrative revenue streams for companies in this sector. Thus, the synergy of rising surgical volumes and innovative drug development is expected to propel market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the General Anesthesia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

General Anesthesia Drugs Market Segments Analysis

Global General Anesthesia Drugs Market is segmented by drug type, Route of Administration, end-use, application and region. Based on drug type, the market is segmented into propofol, sevoflurane, desflurane, ketamine, thiopental, etomidate and others. Based on route of administration, the market is segmented into intravenous and inhaled. Based on end-use, the market is segmented into hospitals, ambulatory surgical centers, clinics and others. Based on application, the market is segmented into cardiovascular surgery, orthopedic surgery, neurosurgery, general surgery, cosmetic surgery and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the General Anesthesia Drugs Market

The growing prevalence of cancer is significantly driving demand in the General Anesthesia Drugs market. With millions of cancer survivors and an anticipated increase in this population, the need for surgical interventions rises, as these procedures often represent the most effective means of treatment when cancer is detected early. Common cancers like lung, breast, and colorectal cancers necessitate surgeries, which typically require general anesthesia for effective management of pain and anxiety. As more patients undergo operations to address various types of tumors, the reliance on general anesthesia will likely intensify, propelling the market forward as healthcare systems adapt to meet these increasing surgical needs.

Restraints in the General Anesthesia Drugs Market

One significant market restraint in the global general anesthesia drugs market is the increasing prevalence of adverse effects associated with anesthetic agents, which raises safety concerns among healthcare providers and patients alike. Reports of side effects such as respiratory complications, allergic reactions, and postoperative cognitive dysfunction can lead to reluctance in the adoption of these drugs. Regulatory bodies are also imposing stricter guidelines on the usage of certain anesthetics, complicating their approval and market entry. Furthermore, the growing interest in alternative anesthesia methods, including regional anesthesia and sedation, may further limit the market's growth potential as clinicians seek safer and less invasive options.

Market Trends of the General Anesthesia Drugs Market

The general anesthesia drugs market is experiencing significant growth driven by robust research and development efforts aimed at enhancing clinical outcomes and patient recovery. A surge in innovative studies assesses the efficacy of various anesthetics, such as inhaled agents and intravenous options like propofol, leading to improved patient experiences. This heightened focus on optimizing anesthetic protocols reflects a broader trend towards personalized medicine, with stakeholders keen on adapting existing drugs and developing new formulations. Additionally, technological advancements and a growing emphasis on patient safety and comfort further bolster market expansion, establishing a dynamic landscape for anesthesia drug development and application.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis

Global General Anesthesia Drugs Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Propofol
Sevoflurane
Desflurane
Ketamine
Thiopental
Etomidate
Others

Global General Anesthesia Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous
- Bolus Injection
- Continuous Infusion
Inhaled
- Volatile Liquids
- Gases

Global General Anesthesia Drugs Market Size by End-Use & CAGR (2026-2033)

Market Overview
Hospitals
Ambulatory Surgical Centers
Clinics
Others

Global General Anesthesia Drugs Market Size by Application & CAGR (2026-2033)

Market Overview
Cardiovascular Surgery
Orthopedic Surgery
Neurosurgery
General Surgery
Cosmetic Surgery
Others

Global General Anesthesia Drugs Market Size & CAGR (2026-2033)

North America (Drug Type, Route of Administration, End-Use, Application)
- US
- Canada
Europe (Drug Type, Route of Administration, End-Use, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Route of Administration, End-Use, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Route of Administration, End-Use, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Route of Administration, End-Use, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun Melsungen AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments